HMy2.CIR细胞

HMy2.CIR/HMy2.CIR细胞系/HMy2.CIR细胞株/HMy2.CIRB淋巴母细胞瘤细胞

Cell line name HMy2.C1R

Synonyms Hmy.2 CIR; HMy2.CIR; C1R

Accession CVCL_3714

Secondary accession CVCL_E511

Resource Identification Initiative To cite this cell line use: HMy2.C1R (RRID:CVCL_3714)

Comments Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Population: Caucasian.

Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.

Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).

Transformant: NCIt; C44386; Gamma radiation.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: B-cell; CL=CL_0000236.

HLA typing Source: IPD-IMGT/HLA=10372

Class I

HLA-A A*02:01

HLA-B B*35:03

HLA-C C*04:01:01

Class II

HLA-DP DPB1*04:01,04:02

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Parent: CVCL_8119 (HMy.2 B)

Children:

CVCL_C0R9 (C1R-A11) CVCL_9U98 (C1R-A2) CVCL_S990 (C1R-A24)

CVCL_S991 (C1R-A31) CVCL_C0RA (C1R-A33) CVCL_J349 (C1R-B27)

CVCL_C5VD (C1R-B*27:02) CVCL_C5VE (C1R-B*27:05) CVCL_6373 (C1R-B7)

CVCL_6374 (C1R-neo) CVCL_6375 (C1R-sB7)

Sex of cell Female

Age at sampling 33Y

Category Transformed cell line

STR profile Source(s): ATCC=CRL-1993

 

Markers:

Amelogenin X

CSF1PO 6,10

D2S1338 17

D3S1358 16

D5S818 10,13

D7S820 7,12

D8S1179 15

D13S317 11,13

D16S539 9,13

D18S51 14,16

D19S433 14,15

D21S11 29,30

FGA 20,21

Penta D 10

Penta E 12

TH01 8

TPOX 8

vWA 17

 

Run an STR similarity search on this cell line

Publications

PubMed=3819393; DOI=10.4049/jimmunol.138.6.1657

Storkus W.J., Howell D.N., Salter R.D., Dawson J.R., Cresswell P.

NK susceptibility varies inversely with target cell class I HLA antigen expression.

J. Immunol. 138:1657-1659(1987)

 

PubMed=2784569; DOI=10.1073/pnas.86.7.2361; PMCID=PMC286912

Storkus W.J., Alexander J., Payne J.A., Dawson J.R., Cresswell P.

Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.

Proc. Natl. Acad. Sci. U.S.A. 86:2361-2364(1989)

 

PubMed=1541831; DOI=10.4049/jimmunol.148.6.1941

Zemmour J., Little A.-M., Schendel D.J., Parham P.

The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon.

J. Immunol. 148:1941-1948(1992)

 

PubMed=30844424; DOI=10.1016/j.humimm.2019.03.001; PMCID=PMC6599558

Creary L.E., Guerra S.G., Chong W., Brown C.J., Turner T.R., Robinson J., Bultitude W.P., Mayor N.P., Marsh S.G.E., Saito K., Lam K., Duke J.L., Mosbruger T.L., Ferriola D., Monos D.S., Willis A., Askar M., Fischer G.F., Saw C.L., Ragoussis J., Petrek M., Serra-Pages C., Juan Otero M., Stavropoulos-Giokas C., Dinou A., Ameen R., Al Shemmari S., Spierings E., Gendzekhadze K., Morris G.P., Zhang Q.-H., Kashi Z., Hsu S., Gangavarapu S., Mallempati K.C., Yamamoto F., Osoegawa K., Vayntrub T., Chang C.-J., Hansen J.A., Fernandez-Vina M.A.

Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: report from the 17th International HLA and Immunogenetics Workshop.

Hum. Immunol. 80:449-460(2019)